Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

Sponsor
Grupo Español Multidisciplinar de Melanoma
Study ID
NCT02439411
Status
Completed

Conditions

  • Malignant Melanoma Stage IIIc
  • Malignant Melanoma Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.

Key Dates

Start date
Mar 3, 2015
Status verified
Nov 2019
Primary completion
Sep 30, 2016
Completion
Sep 30, 2016

Study Design

Enrollment
135 participants (actual)

Arms

  • Arm: Dabrafenib
  • Arm: Dabrafenib plus Trametinib
    Patients treated with Dabrafenib plus Trametinib

Primary Outcome Measure

Best Overall Response [ Time Frame: Up to 18 months ]

Related Studies